Search results
Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush
FierceBiotech· 11 hours agoA patient with lupus nephritis in a phase 1/2 clinical trial of Kyverna Therapeutics’ CAR-T...
Biotech With 345% Run Posts A 'Clear Win' In Cancer Treatment
Investor's Business Daily· 4 hours agoThe company tested its treatment, dubbed NX-5948, in patients with relapsed or refractory forms of...
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 8 hours agoRegeneron is continuing its extensive OLYMPIA programme, which includes Odronextamab, with ten...
‘A ticking time bomb’: Grieving mother’s warning over deadly Chinese opioid epidemic
The Independent via Yahoo News· 6 hours agoAt up to 500 times stronger than morphine, even the most minute doses can prove fatal. But Dylan,...
Siemens Healthineers nets European approval for blood test to predict MS relapse risks
FierceBiotech· 8 hours agoSiemens Healthineers received European approval for a blood test designed to help predict the risk...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 11 hours agoCT071 is CAR T cell drug that acts by binding to cells expressing GPRC5D. It was developed using...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks· 19 hours agoFree Report) announced positive results from the late-stage STARGLO on the blood cancer drug Columvi (glofitamab). The STARGLO study is a phase III, multicentre, open-label ...
Dr. Jeffrey Wheeler and Donnica Carpenter: Relapse amid recovery isn’t a failure. It’s a time to...
Indianapolis Business Journal· 4 days agoThe National Institute of Drug Abuse lays the facts out clearly: 40%-60% of people receiving...
...Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse...
Morningstar· 2 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma – The study met ...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 15 hours agoELREXFIO is a B-cell maturation antigen (...multicentre trial assessed ELREXFIO monotherapy in...